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Abstract 
The total number of identified rare Mendelian disorders is currently  estimated to be around 7,000, 
and while each is individually rare, together, these genetic conditions contribute significantly to 
morbidity, mortality, and healthcare costs.  
In the last decade, there has been a paradigm shift in the investigation of Mendelian disorders, due 
to the development of powerful new DNA sequencing technologies, commonly referred to as Next-
Generation Sequencing (NGS). Whole exome sequencing (WES) is an NGS method that analyzes all 
protein-coding regions (exons) of genes in the genome. When compared with other methods WES 
has the critical advantages that it does not require any a priori hypothesis about the nature of the 
defective genes and that it offers a high coverage of the exons.  Considering that exonic mutations 
cause the vast bulk of Mendelian disorders, currently WES is thus the most powerful approach for 
Mendelian gene identification. Still, despite the recent progress in knowledge of the diversity of 
Mendelian phenotypes largely due to WES, substantial gaps remain. Up to 50% of patients affected 
by a rare genetic disorder never receive a diagnosis. 
Diagnosis depends on gene discovery, and early diagnosis is crucial to establish an adequate 
treatment and to identify novel knowledge-based therapeutic targets to improve the overall 
outcome.  
We focused our attention on such rare Mendelian disorders, and in a collaborative effort, we 
studied by WES a cohort of heterogeneous samples affected by the following disorders: Crisponi 
syndrome/Cold-induced sweating syndrome type 1 (CS/CSS1)-like, syndromic Intellectual 
Disabilities and Epileptic Encephalopathies (EE). 
The results of our work led to the finding of both recessive and dominant pathogenic variants of 
human NALCN associated complex neurodevelopmental syndromes. Recessive pathogenic variants 
of NALCN are linked to the infantile hypotonia with psychomotor retardation, and characteristic 
facies type 1 syndrome (IHPRF), while dominant pathogenic variants of NALCN are responsible for 
the congenital contractures of limbs and face, hypotonia and developmental delay syndrome 
(CLIFAHDD). The discoveries of pathogenic variants in NALCN, MAGEL2 and SCN2A, allowed us to 
reassess the clinical phenotype of patients with a suspect of CS/CISS1-like syndrome, respectively 
into CLIFAHDD, SHFYNG or EIEE11 syndromes, and although they present with overlapping features 
especially in infancy, such as feeding problems, contractures and temperature instability, they must 
be considered as distinct entities. These results showing a high neonatal phenotypic overlap among 
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CS/CISS1 with the other known syndromes will be very helpful for clinicians. Although clinical 
expertise allows in some cases to make a confident clinical diagnosis, adequate counselling should 
only be possible after the diagnosis has been confirmed by molecular genetic testing. Furthermore, 
the finding of variants in the imprinted MAGEL2 locus shows the importance to consider also 
complex genetic mechanisms, such as genomic imprinting in search of pathogenic variants 
underlying Mendelian disorders. 
Our finding of a pathogenic de novo variant in a particular region of the CREBBP gene, implicated in 
the Rubinstein-Taybi syndrome-1 (RSTS1) but associated to a different clinical phenotype, helped to 
establish genotype-phenotype correlations in this disorder, and to define it as a distinct clinical 
entity distinct from RSTS1, called Menke-Hennekam syndrome (MKHK1), to provide an adequate 
name for its identification by parents and specialists, thus facilitating appropriate clinical 
management and research.  
Furthermore, the discovery of a novel de novo variant in ANKRD11 causing a mild phenotype of KGB 
syndrome associated to a SCN9A variant causing GEFS+, offers an example of how WES has been 
instrumental allowing us to better dissect the clinical phenotype under study, which is a multilocus 
variation aggregating in one proband, rather than a phenotypic expansion associated with a single 
genomic locus, underscoring the role of multiple rare variants at different loci in the aetiology of 
clinical phenotypes making problematic the diagnostic path. The successful identification of the 
causal variant in a gene may not be sufficient, making it necessary to identify other variants that 
help fully explain the clinical picture. The prevalence of blended phenotypes from multiple 
monogenic disorders is currently unknown and will require a systematic re-analysis of large WES 
datasets for proper diagnosis in daily practice. 
These results along with others reported in the literature, are contributing to reveal the extensive 
clinical variability and genetic complexity underlying Mendelian phenotypes and inheritance, to 
provide insight into study design and approach and analytical strategies and to identify novel 
mechanisms.  
Our increasing knowledge on the genetic basis of rare disorders is shedding light on the “complex” 
nature of the “simple” Mendelian disorders and that “true monogenic” disorders are very rare. 
These complex relationships between Mendelian conditions and their associated genes and 
phenotypes underscore the current challenges of clinical diagnostics and discovery. The goal of 
identifying and characterizing the molecular architecture of Mendelian conditions would rely on the 
ability to detect with sufficient sensitivity and specificity the relevant types of variants and their 
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Mendelian or monogenic disorders are the kind of genetic disorders in humans that arise from a 
disease-associated variant in a single gene. The term “Mendelian” is used because single-gene 
disorders run in families according to Mendel’s laws and can be dominant or recessive, and 
autosomal or sex-linked (Chial et al., 2008).  
Variants causing Mendelian disorders are typically rare (minor allele frequency or MAF<1% in the 
population) since they tend to be negatively selected from the population owing to their extremely 
deleterious effects, and highly penetrant because nearly all individuals who carry a particular variant 
also express the associated phenotype. Therefore, Mendelian disorders are rare, with a prevalence, 
stated as the number of cases present in a population, that in the European Community has been 
defined as 5 cases per 10,000 people (https://www.eurordis.org). 
The prevalence of genetic disorders varies widely between diverse geographical areas due to 
different population organization and structure, reproductive practices and environmental factors. 
According to a recently published research, rare disorders currently affect around 4% of the 
worldwide population, equivalent to a conservative estimate of 300 million people worldwide 
(Nguengang Wakap et al., 2019). They are characterized by a wide variety of illnesses and symptoms. 
Rare disorders are severe, often chronic, essentially disabling and the patients’ quality of life is 
affected by the lack or loss of autonomy due to the chronic, progressive, degenerative, and 
frequently life-threatening aspects of the disorder (https://www.rarediseaseday.org). The 
difficulties in access to treatment and care often results in heavy emotional, social and financial 
burdens on patients and their families (https://www.eurordis.org). 
Rare disorders often go undiagnosed because patients, families and physicians have limited 
awareness of the condition, and rare disorder symptoms may not always be evident to healthcare 
providers who have never encountered it (https://www.globalrarediseasecommission.com). 
Besides, clinical variability and genetic heterogeneity can complicate the diagnosis, and common 
related symptoms can hide rare disorders, leading to misdiagnosis. This often results in the so-called 
“diagnostic odyssey”, a succession of steps, starting from the onset of symptoms to diagnosis of the 
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disorder which every person affected by a rare disorder goes through. According to an international 
online survey, approximately 40% of rare disorder patients received a misdiagnosis at least once, 
and the average time to an accurate diagnosis after symptoms have appeared is approximately 4.8 
years (https://www.globalraredisordercommission.com; Engel et al., 2013). 
Delays in diagnosis can lead to improper disorder management as well as disorder progression, and 
a misdiagnosis can lead to additional interventions later deemed to be inappropriate given the 
underlying disorder (https://www.globalraredisordercommission.com). 
The field of rare disorders suffers from a deficit of medical and scientific knowledge. For a long time, 
doctors, researchers and policymakers were unaware of rare disorders, and until very recently, 
there was no real research or public health policy concerning issues related to the field 
(https://www.orpha.net). 
Currently, two international databases curate clinical and genetic data for the community: Online 
Mendelian Inheritance in Man (https://www.omim.org/) and Orphanet (https://www.orpha.net/). 
Online Mendelian Inheritance in Man® (OMIM®), is the primary repository of comprehensive, 
curated information on human genes and genetic phenotypes and the relationships between them, 
freely available and updated daily. This database was firstly published in 1996 by Dr Victor A. 
McKusick as a catalogue of Mendelian traits and disorders, entitled Mendelian Inheritance in Man 
(MIM). The online version, OMIM, was created in 1985 by a collaboration between the National 
Library of Medicine and the William H. Welch Medical Library at Johns Hopkins. At present (as 
October 25th, 2019), it has over 25,000 entries describing over 16,000 genes (of approximately 
~19,000 protein-coding genes predicted to exist in the human genome) and 8,900 phenotypes. All 
entries in OMIM are given unique and stable MIM numbers. Genes and phenotypes are described 
in separate entries. Analysis of the discovery metrics at present shows that variants causing 5,470 
Mendelian phenotypes have been identified in 3,790 genes (~20%). Genes underlying 1,555 (~8%) 
Mendelian phenotypes have been mapped but not identified. Genes underlying 1,749 (~9%) 
suspected Mendelian phenotypes had been not yet identified either mapped. Genes whose impact 
in humans has not yet been determined are ~12,000. Based on the analysis of knockout mouse 
models, loss of function variants in up to ~30% of genes (~6,000) could result in embryonic lethality 
in humans. Collectively, ~16,000 genes remain candidates for Mendelian phenotypes, with a rate of 
new genes associated with Mendelian conditions per year of about 300 (Chong et al., 2015). 
Orphanet has maintained a register of both genetic and other rare disorders since 1997 and aims to 
collect epidemiological data on every rare clinical entity included in its nomenclature 
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(https://www.orpha.net/). While OMIM categorizes rare disorder on the basis of genetic etiology, 
Orphanet groups by clinically recognizable disorders. Furthermore, the Orphanet nomenclature of 
rare disorders is being annotated with the Human Phenotype Ontology (HPO) terms in order to 
allow for deep phenotyping of rare disorders in health records and registries. The HPO was initially 
published in 2008 (http://www.human-phenotype-ontology.org; Köhler, 2018) with the goal to 
provide a standardized vocabulary of phenotypic abnormalities encountered in human disorder, so 
enabling the integration of phenotype information across scientific fields and databases, providing 
comprehensive bioinformatic resources for the analysis of human disorders and phenotypes, 
offering a computational bridge between genome biology and clinical medicine.  
Several genes responsible for rare Mendelian disorders have been identified beginning in the mid-
1980s, and for the following two decades, by an approach to gene discovery that was a combination 
of linkage analysis, positional cloning and Sanger sequencing of candidate or mapped genes, most 
of which was hypothesis-driven (Boycott et al., 2017). However, factors such as the reduced 
availability of affected subjects and families to study, the heterogeneity of locus and the reduced 
reproductive fitness often limit the power of these conventional approaches (Ng et al., 2010). The 
subsequent introduction in 2009 (Ng et al., 2009) of hypothesis-free next-generation DNA 
sequencing (NGS), primarily whole-exome sequencing (WES) strategies provided an alternative 
method to identify genes associated with the disorder through the study of information contained 
within the human genome. This has resulted in increased identification of rare disorder genes, many 
of which were previously intractable to conventional gene discovery approaches.  
The first monogenic disorder to be solved by WES was Miller syndrome, a multiple malformation 
disorder (Ng et al., 2010). Since then, WES became the primary technological approach for 
Mendelian disorder gene identification. 
WES has the critical advantage of permitting the finding of both known and novel disorder-causing 
genes at the same time and considering that, in 85% of cases variants causing Mendelian disorders 
map within protein-coding sequences or in canonical splicing sites, currently it is the best approach 
for Mendelian gene identification (Choi et al., 2009). 
For the first time, this technology has been proved to be successful in the identification of rare and 
extremely rare variants causative of the clinical phenotype under study (minor allele frequency; 
MAF <1% and < 0.5% respectively) also with small numbers of informative cases (one trio or few 
unrelated individuals with the same phenotype), which have been refractory to classical 
approaches. It is possible to study different patterns of inheritance (recessive, dominant/de novo, 
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X-linked) with the appropriated strategy of variant filtering (Gilissen et al., 2012). We can assume to 
look for bi-allelic variants for a recessive model (homozygous or compound heterozygous and the 
parents to be obligate carriers for the variant); heterozygous variant for a dominant model (only 
one parent obligate carrier for the variant or none in case of a de novo event); homozygous or 
hemizygous variant for an X-linked model. Genes for recessive disorders are, in general, more 
accessible to find than genes for dominant disorders because fewer genes in each exome are 
homozygous or compound heterozygous for rare non-synonymous variants (Gilissen et al., 2012). 
The benefits of exome sequencing studies are clear (Bamshad et al., 2011): 
 cost-effective and rapid strategy for analyzing nearly all the coding regions of the genome; 
 unbiased sequencing approach, because it does not limit the analysis to a predefined region, 
so it is possible to identify genes acting in unexpected pathways or cellular processes; 
 sample size required for a sufficiently powered study dramatically reduced (few 
phenotypically unrelated individuals, a single extended family, or a single parent and child); 
 provides new insights into human gene pathways; 
 crucial for drawing accurate genotype/phenotype correlations, 
 facilitate clinical diagnostic, both in cases that present with atypical manifestations, or that 
require extensive or costly evaluation (high genetic heterogeneity), opening the way to a 
specific choice of treatment. 
Although the advantages of sequencing the exome are evident, it also has some limitations. WES 
was designed to find variants in coding regions and UTR’s such as single nucleotide polymorphisms 
(SNPs), small insertions and deletions (indels). Therefore, most of the non-coding variants escape 
the technology itself, along with others such as trinucleotide repeats and chromosomal 
rearrangements. Large deletions and duplications (Copy Number Variants or CNVs) are also 
challenging to be detected from exome data, although several tools have been developed. The four 
well known WES-based CNVs detection tools HXMM, CoNIFER, ExomeDepth, and CONTRA, use each 
an algorithm that has its strengths and weaknesses, different minimum and maximum CNV length 
detection, accuracy. Usually, the majority of the software is based on the analysis of the read depth 
detecting the number of fragments that mapped in defined genomic regions, and on the comparison 
between patient and controls data. However, these measures could be affected by errors caused by 
inaccurate capture of the region for capture kit problem or alignment problems so that they should 
always be confirmed by another technique (de Ligt et al., 2013).  
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The more significant challenge, however, is data interpretation. On average, exome sequencing 
identifies about 20,000 – 25,000 single nucleotide variants (SNVs), a number that can change in 
consideration of various factors such as different methods used, and ethnicity of samples. More 
than 95% of these variants are known polymorphisms in human populations. (Bamshad et al., 2011; 
1000 Genomes Project Consortium, 2010).  
In this context, the strategies to search causal alleles are different and take into account several 
factors (Bamshad et al., 2011): 
• mode of inheritance of the trait; 
• pedigree or population structure; 
• de novo or inherited variant; 
• extent of locus heterogeneity; 
• allele frequency; 
• biological function of each variant; 
• analysis of network-disorders. 
Another challenge is also to get a comprehensive clinical phenotype that can help to address the 
search towards a particular gene/pathway. Sometimes WES reveals mutations that help the 
clinicians to make the proper diagnosis, and this type of approach, genotype-driven is called 
“reverse phenotyping” (Schulze and McMahon 2004). 
While taking into account the complexity of interpretation, the enormous potential of WES explains 
why it is becoming the first-choice method in laboratories dealing with molecular diagnostics, with 
an overall diagnostic rate in unselected, consecutive patients reported to be∼25%-40% (Dragojlovic 
et al. 2018). This variable range across different studies probably is due to several factors including 
sequencing approaches, analysis strategies, family history, type of disorder, age at presentation, 
variant interpretation (Ji et al., 2019).  
 
Rationale of the work 
Although substantial progress has been made toward identifying the genetic basis of Mendelian 
disorders, more than 50% of patients affected by a rare genetic disorder never receive a diagnosis, 
crucial to establish an adequate treatment and to identify novel knowledge-based therapeutic 
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targets to improve the overall outcome (Boycott et al., 2017). Diagnosis depends on gene discovery, 
and for Mendelian disorders, science can provide some answers.  
The accurate understanding of the genetic bases of Mendelian disorders is hugely relevant for 
various reasons concerning 1) to formulate a precise diagnosis and therefore to provide the parents 
of the affected subjects with an explanation of the severe pathology of their children; 2) to offer, 
through an adequate genetic consultation, exact estimates of the risk of recurrence allowing the 
parents of these subjects to plan, in an informed manner future reproductive strategies; 3) to 
provide molecular tools for a possible prenatal diagnosis in future pregnancies where the parents 
would freely use this option; 4) to indicate potential therapeutic targets useful for the development 
of new drugs based on a full understanding of the pathophysiological mechanisms of each form of 
disorder and to create the conditions for approaches of personalized medicine. 
For this purpose, multiple and integrated research programs are necessary, including the collection 
of clinically well-characterized patients and their families for genotype/phenotype correlations, 
genetic studies covering the whole genome/exome, genetic and biological validation of the 
potentially disorder-associated variants identified with functional characterization of the 
transcriptional and protein products of the candidate genes. Only through this primary research 
activity will it be possible to arrive at the subsequent transfer of the acquired knowledge to the 
diagnostic and therapeutic field. Since the first successful application for gene discovering in rare 
Mendelian disorders of unknown cause (Ng et al., 2010), WES turned out to be a powerful approach 
to detect high penetrance disorder-associated variants. 
The rationale of this proposal is to contribute to the identification of the disorder causing genes by 
WES in molecularly unsolved cases with a family history of a rare disorder. 
We focused our attention on a cohort of heterogeneous samples affected by the following 
disorders: Crisponi syndrome/Cold-induced sweating syndrome type 1 (CS/CSS1)-like phenotype, 
Epileptic Encephalopathies (EE) and syndromic Intellectual Disabilities (SID), Some samples are of 
Sardinian origin. Sardinia is a founder population in which the frequency of particular alleles can be 
higher than that in large populations, a cause of genetic drift, natural selection and bottleneck. Its 
population has already proved extremely useful for mapping genes implicated in rare disorders. 
Furthermore, the availability of a reference Sardinian genome database generated at the CNR 
Institute of Genetic and Biomedical Research (IRGB), from the sequencing of the entire genome of 
3500 Sardinian individuals from different areas of the island (Sidore et al., 2015) can help to 1) 
discriminate specific Sardinian variants 2) make a more accurate estimate of the allele frequency; 
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3) identify sub-regions within the island where the frequency of carriers for a particular causal 
variant is higher, suggesting a possible founder effect. 
The centres involved in the study have been the following: 
1. Department of General Pediatrics, Muenster University Children’s Hospital (Germany) for 
the collection and clinical phenotyping of CS/CISS1-like phenotype individuals. 
2. Epilepsy Unit, Department of Neurology and Paediatrics Psychiatry, A. Cao Hospital, AOB, 
Cagliari (Italy) and Research group Epi-Genétic, Salvador, Bahia (Brazil), for the collection 
and clinical phenotyping of individuals with Epileptic Encephalopathies. 
3. Institute of Child Neuropsychiatry, University of Sassari and AOS (Italy) for the collection 
and clinical phenotyping of individuals who have syndromic Intellectual Disability. 
4. Institute for Genetic and Biomedical Research, National Research Council, Monserrato 
(Italy) for the generation of WES data and genetic analysis. 
5. Research, development and higher education centre in Sardinia (CRS4), Pula (Italy) for the 
generation of WES data and bioinformatics analysis. 
 
Mendelian disorders under study 
Crisponi Syndrome/Cold-induced sweating syndrome type 1 (CS/CISS1)-
like phenotypes 
Text extract from Buers et al., 2019: “Crisponi syndrome (CS, MIM#601378) was firstly described in 
Sardinian families and although some phenotypic overlap existed with other phenotypes, the 
syndrome was hypothesized to be a unique entity and a new syndrome.1 Later on, Accorsi et al2 and 
Nannenberg et al3 reported further patients with an identical phenotype, and suggested to name 
the entity Crisponi syndrome. CS is a rare recessively inherited disorder with a high neonatal lethality. 
The principal clinical symptoms are recurrent periods of hyperthermia, camptodactyly, feeding and 
respiratory difficulties induced by abnormal paroxysmal contractions of the facial and oropharyngeal 
muscles. Some CS individuals survive the first year of life and often display a spontaneous 
improvement of feeding difficulties and hyperthermia.1,4 However, these individuals develop 
scoliosis, sometimes mild psychomotor retardation as well as cold-induced sweating combined with 
massively elevated plasma noradrenaline (NA) levels in early childhood.5 Cold induced sweating 
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syndrome type 1 (CISS1) was initially described in two siblings at the age of 20 and 21 years.6 They 
showed cold induced sweating at ambient temperatures lower than 20°C. A retrospective study 
revealed that most of the patients showed crises of hyperthermia, respiratory difficulties or 
contractions of facial and oropharyngeal muscles in infancy, typical symptoms of CS.7 Scoliosis as 
well as other dysmorphic features are additional symptoms of this syndrome. Both, CS and CISS1 are 
caused by variants in the cytokine receptor like factor 1 (CRLF1) gene, coding for a ligand of the 
ciliary neurotrophic factor receptor (CNTFR).4,8,9 Genetic and functional studies on altered CRLF1 
indicated that CS and CISS1 are two occurrences of the same disorder. Thus, CS is considered as the 
infantile presentation of CISS1.10,11 CS/CISS1 belongs to the family of “CNTFR-related disorders” with 
overlapping clinical features including cold-induced sweating syndrome type 2 (CISS2, MIM#610313) 
and Stüve-Wiedemann Syndrome (STWS, MIM#601559). CS/CISS2 is caused by variants in 
cardiotrophin-like cytokine factor 1 (CLCF1),7,12,13 and STWS by variants in leukemia inhibitory factor 
receptor (LIFR).14 
The combination of typical clinical CS/CISS symptoms and the detection of disorder-associated 
variants in CRLF1 or CLCF1 are the prerequisites for diagnosis. Alterations in CRLF1 and CLCF1 can be 
found in more than 60% of individuals with clinical diagnosis of CS/CISS, and a subset of CS/CISS 
cases (about 40%) remains yet genetically unexplained (CS/CISS-like phenotypes). 
The differential diagnosis in CS/CISS has rapidly changed with the use of next generation-based 
sequencing techniques. Variants in genes others than those related to the family of “CNTFR-related 
disorders” have been recently found to be associated with a CS/CISS-like phenotype. In 2016, disorder 
causing variants in kelch like family member 7 (KLHL7) were detected in individuals with a CS/CISS-
like phenotype associated with retinitis pigmentosa (RP).15”  
Epileptic Encephalopathies (EE) 
Epileptic encephalopathies (EE) include a large and heterogeneous group of severe epilepsies with 
genetic aetiology. In the last two decades, the so-called molecular revolution in medicine has also 
had an essential impact in the diagnosis and treatment of EE, and genetic research in this field is 
currently a highly suggestive and promising study frontier (Gobbi et al. 2014).  
Epileptic Encephalopathies (EE) is a group of epilepsies typically at pediatric-onset and often severe, 
characterized by frequent and intractable seizures, severe disruption of brain electrical activity and 
cognitive arrest or regression, in which epilepsy in itself contributes to aggravate the cognitive and 
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behavioural deterioration of the subject. This category includes about 40% of epilepsies in the first 
three years of life (Nieh and Sherr, 2014). 
The first genetic cause for a form of EE was first recognized in 2001, with the discovery of a de novo 
mutation in the SCN1A gene associated with Dravet's syndrome (Claes et al., 2001). Subsequently, 
with the advent of new genomic technologies, such as the CGH array (Comparative Genomic 
Hybridization), the NGS and in particular the WES, the number of mutated genes involved in EE has 
grown rapidly leading to the identification to date of more than 70 genes (Helbig and Tayoun, 2016).  
Recent studies show that the application of NGS techniques through the sequencing of specific 
multigenic panels for epilepsy and/or exomic sequencing allows to reach a diagnostic yield of 20-
40% for EE (Chambers et al., 2016; EuroEPINOMICS-RES Consortium, 2017; Helbig et al., 2016; 
Kwong et al., 2015; Trump et al., 2016), increasing cost-effectiveness and significantly reducing the 
time of the diagnostic odyssey that families with EE encounter before receiving a definite diagnosis. 
Genetic mechanisms underlying epilepsies known to date include genomic rearrangements (ring 
chromosomes, translocations, monosomies and trisomies), copy number variants (CNVs; 
submicroscopic rearrangements, deletions or duplications involving one or more genes) and 
alterations of individual nucleotides that result in missense, frameshift or nonsense mutations. 
However, despite the progress made in recent years, the aetiology of about 80% of EE forms remains 
unexplained, probably due to the high genetic and phenotypic heterogeneity. The emerging genetic 
architecture has led to a better understanding of the pathophysiology of EE syndromes, but still very 
limited. In the last decade, several pathophysiological mechanisms involved have emerged, 
including dysfunction of the ion channels, deficit in synaptic transmission, alterations of the mTOR 
signal pathway, chromatin remodelling and transcription regulation (von Deimling et al., 2017; 
Myers and Mefford, 2016; Epi4K Consortium et al., 2013). This led to the identification of different 
pharmacological targets for the various types of epilepsies. Therefore, it is critical to know the 
genetic cause in the patient in order to find the optimal treatment. Genetic mutations causing EE 
are mostly sporadic, i.e. resulting from de novo mutations in a single autosomal dominant 
expression gene, but there are also autosomal recessive EE forms and X-linked forms (Gobbi et al., 
2014). Moreover, it has already been demonstrated that: similar mutations can be associated with 
different epileptic syndromes (variable expressivity), two individuals carrying the same genetic 
mutation have a different probability of developing epilepsy (incomplete penetration), and the 
same monogenic epileptic syndrome can be caused by mutations in different genes (genetic 
heterogeneity, Gardiner, 2006). These aspects explain why the relationship between genotype and 
 Dott.ssa Laura Crisponi 
How exome sequencing is shedding light on the complexity of Mendelian disorders: some examples from Sardinia 
Tesi di Dottorato in Scienze Biomediche, Curriculum: Genetica Medica XXXII ciclo, Università degli Studi di Sassari  Pag. 13 
 
epileptic phenotype is not always linear and why within EE similar syndromic pictures may be 
associated with different gene mutations and, on the contrary, why pictures are not always linear. 
Syndromic Intellectual Disability (SID) 
Intellectual Disability (ID) until recently defined as Mental Retardation (MR), is a condition defined 
by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), as characterized 
by significant limitations in intellectual functioning and adaptive behavior, which include 
conceptual, social, and practical skills, arising "prior to age 18" (Chiurazzi and Pirozzi, 2016). It is not 
a single disorder with defined signs and symptoms, but it represents, especially in its syndromic 
forms, a wide variability of clinical phenotypes who have, as a common trait, a compromised 
intellectual capacity. People affected by ID need social support and specific educational services in 
order to achieve the skills necessary for the autonomy of daily life. Clinically it is defined by three 
main criteria (Van Bokhoven, 2011): 
1. an intelligence quotient (IQ) below 70; 
2. limitations in two or more adaptive behaviours, such as communication, self-care, and social skills; 
3. age at onset of mental manifestations before 18 years old. 
ID is the most common developmental disorder and clinically can be distinguished as syndromic or 
not in case is associated with other clinical findings such as dysmorphic features, multiple congenital 
abnormalities or metabolic defects as part of a syndrome. Together, the syndromic and non-
syndromic forms of ID affect about 1% of the population (Maulik et al., 2011), with life-long care 
costs that can be extremely high along with dramatic repercussions at the emotional and social level 
of the affected and their families. 
Although the development and functioning of the nervous system, prenatal, perinatal and 
postnatal, may be influenced by non-genetic factors (such as infections, trauma, exposure to 
neurotoxic substances), resulting in cognitive impairment, most severe forms of ID have a genetic 
origin. Although the percentage varies in different studies, it was found that hereditary forms can 
account for up to 65% of moderate and severe forms of ID (Van Bokhoven, 2011). 
Based on our current knowledge, the genetic causes of ID include: 
• chromosome rearrangements that result mainly in deleterious effects of the dosage gene 
(about 30% of cases, Topper et al., 2011); 
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• mutations and deregulation of genes or genomic regions subject to imprinting for the 
transcriptionally active allele variant depending on its parental origin (rare cases, like 
Prader Willi and Angelman syndromes); 
• dysfunction of individual genes (monogenic causes of ID), which are individually needed 
for development of cognitive functions (about 10% of these are X-linked; Topper et al., 
2011, Chelly et al., 2006). 
So far, mutations have been identified in about 700-800 genes causing both non-syndromic and 
syndromic ID (Vissers et al., 2016, Chiurazzi and Pirozzi, 2016) and the functions of their respective 
proteins are very different. Although the number of involved genes has rapidly increased with the 
introduction of NGS technologies, still many ID genes are to be discovered, and although it is difficult 
to predict the number, an estimation of about 1,000 is likely (Vissers et al., 2016). 
Recent studies confirm the importance of de novo mutations in larger cohorts with unexplained 
severe ID; therefore, the WES in this context is a necessary diagnostic test (Vissers et al., 2016).  
The increase in the number of ID genes being identified, show extended and complex functional 
interaction networks converging into common molecular and cellular pathways, including 
neurogenesis, neuronal migration, synaptic functions, transcription and translation. 
Additionally, Gene Ontology (GO)-based annotations of multiple biological processes in several 
studies revealed that ID risk genes are significantly associated with nervous system development, 
RNA metabolism, and transcription, presenting convergent functional features in specific biological 
pathways that reflect the complexity underlying the development of a functional brain (Kochinke et 
al., 2016, Liu et al., 2018). 
There is growing evidence that mutations in many of the known ID genes give rise to a high degree 
of clinical variability, that can be a reflection of the type of mutation or other genetic and 
environmental factors, and to the association with a variety of different Cognitive Disorders (CDs). 
There is a high co-morbidity commonly observed between ID and other CDs, such as autism (ASD), 
attention deficit hyperactivity disorder (ADHD), depression and other behavioural problems. This 
phenotypic overlap between ID and various CDs is mirrored at the genetic level, all supporting the 
notion that they share a common molecular aetiology. 
Genetic studies are showing the increasing inheritance complexity in ID, and genotype-phenotype 
correlation studies indicate that phenotypes are only rarely explained entirely by a mutation in a 
single gene, and other variations may affect the expressivity and penetrance of the disorder. 
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To date, more than 800 genes are known to be involved in the pathogenesis of syndromic and non-
syndromic conditions with ID (Chiurazzi and Pirozzi, 2016), and the functions of their respective 
proteins are very different. Although the number of ID genes is increasing rapidly, currently the 
genetic aetiology of 60% of ID remains unexplained (Topper et al., 2011), and the majority of 
patients remains without a molecular diagnosis. 
 
Methods 
Patients’ selection, samples acquisition and DNA extraction 
We have selected seven families with different rare disorders to be enrolled in this project, aiming   
to discover new genes involved in their pathogenesis by applying the WES approach. The selected 
families were affected by: 
- Crisponi syndrome/Cold-induced sweating syndrome type 1 (CS/CISS1)-like phenotypes; five 
families of various ethnicities, were recruited in collaboration with Prof. Frank Rutsch from 
the Department of General Pediatrics, Muenster University Children’s Hospital, Muenster 
(Germany). 
Text extract from Angius et al., 2019: “Five individuals with the initial diagnosis of CS/CISS but 
negative for mutations in CRLF1 and CLCF1 were clinically assessed by the respective clinical 
geneticists and selected for WES analysis. Clinical findings of these cases are listed in Table 1. Our 
inclusion criteria comprised features related to the neonatal phenotype and especially to the four 
main typical CS criteria: hyperthermia in the first months of life, feeding difficulties, contraction of 
oropharyngeal muscles and camptodactyly. We assigned the five cases to rank 1 (very likely) and 2 
(questionable) based on their phenotype similarity to CS/CISS. Rank 1 individuals (CS_239 and 
CS_306) presented in the neonatal period the four main typical CS criteria, while rank 2 (CS_125, 
CS_141 and CS_207) individuals fulfilled two or three of them (See clinical details and WES analysis, 
Supporting Information, Table S1).”  
- Epileptic Encephalophaties (EE); one Sardinian and one Brazilian family, recruited in 
collaboration with Dr. Pruna from the Epilepsy Unit, Department of Neurology and 
Paediatrics Psychiatry, A. Cao Hospital, AOB, Cagliari (Italy) and Dr. Alves from the Research 
group Epi-Genétic, Salvador, Bahia (Brazil). 
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Sardinian cases - Text extract from Angius et al., 2018: “Two siblings of a Sardinian family presenting 
with dysmorphic facies, hypotonia, psychomotor retardation, epilepsy, absent speech, sleep 
disturbance, hyperkinetic movement disorder, cachexia and chronic constipation. Both siblings 
experienced generalized seizures with age at the onset of 4 and 6 years. They present a disorganized 
electroencephalogram (EEG), and bi-frontal and diffuse high amplitude sharp/slow waves are 
evident. Particularly, male proband EEG has a high frequency of epileptic discharges. Despite a 
recent moderate improvement, his electric activity is much more impaired than that in his sister. 
Furthermore, he has weekly seizures, mainly during sleep, and no response to anti-epileptic drugs 
(AEDs), while AEDs treatment was efficient in the female, with lack of seizures. Clinical and EEG 
pictures of our cases are very similar to those described for UNC80- mutated cases (Figure 1). The 
dysmorphic features are triangular face, bi-temporal narrowing, high nasal bridge, downslanting 
palpebral fissures, posterior rotated low set-ears, large and persistently opened mouth, and long 
fingers. Since the first months of life, they showed severe generalized hypotonia, but they could 
maintain in sitting position without support. They are unable to develop speech and present severe 
intellectual disability and sleep disturbances. Hyperkinetic movement and autistic spectrum disorder 
are evident”. 
Brazilian case - Text extract from Alves et al., 2019: “Female 14.5 years old. Delivered full term, by 
emergency C-section, due to lack of fetal movement, weighing 2.971 Kg, 48 cm long and 33 cm head 
circumference. Neonatal period had no complications. From the neonatal period onward, she 
showed difficulty to breastfeed, with low weight gain. At 9 months old, she had mioclonus-atonic 
type seizures with sudden falling of the head and trunk. Initially precipitated by fever, these seizures 
became afebrile and daily, several times a day, and were controlled after substituting phenobarbital 
for sodiumvalproate (VPA), in low doses. The EEG tests initially showed focal spikes (centro-temporal 
regions) and only at 4 age, one EEG test showed a theta rhythm (4-5 Hz) in the temporo-occipital 
regions (T5-O1; T6-O2). At the age of 4 years and 8 months, after remission of seizures for 3 years, 
and normal EEG tests, VPA was suspended. Starting from 6 years of age, the EEG tests showed 
persistence of several bursts of irregular generalized polyspike-wave (PSW) and spike-wave 
discharge (SW), lasting 1–3 s. (Fig. 1a-p). Despite persisting abnormal EEGs, patient has not 
presented relapse of seizures and is not on medication. Patient presented with recurrent otitis 
episodes and developed conductive hearing loss in left ear. A computed tomography scan of the 
mastoid showed signs of otomastoiditis in the left ear with obliteration of Prussak’s space and 
cholesteatomatous process. Orthodontic evaluation conducted at 8 years of age showed 
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dolichofacial pattern, maxillary protrusion, absence of lip seal, delayed eruption of permanent teeth, 
besides size increase of upper central incisors, with extra mamelar structures and whitish material 
of incisors and other teeth, compatible with hypoplasia (Fig. 2a, b). Cone-beam computed 
tomography of right oral lower-posterior region at 14.5 years of age, revealed dental units partially 
erupting and the presence of mixed-aspect images located between the dental roots, suggesting 
bone dysplasia (Fig. 2). The skeletal X-ray assessment showed inversion of physiological cervical 
lordosis (Fig. 2c); deviation of left dorsal axis, accen- tuated thoracic and lumbar lordosis and 
concealed spina bifida at L5/S1 (Fig. 2f). The proband has also shortening of the distal phalanx of the 
5th finger, clinodactyly of the 2th and 5th (Fig. 2d, e); myopia; bifid uvula with submucous cleft 
palate; weight and height growth curve below percentile <5. Neuro- psychological analysis at age 8 
showed IQ of 73.”  
- Syndromic Intellectual Disability (SID); one Sardinian family, recruited in collaboration with 
Prof. Sotgiu and Dr. Serra from the Institute of Child Neuropsychiatry, University of Sassari 
and AOS (Italy). 
Text extract from Angius et al., 2019: “The proband II.4 is 17-year-old boy born to a Sardinian family 
with unrelated parents, and two older healthy siblings (Figures 1 and 2a). The mother had one 
miscarriage at the fourth month of pregnancy (II.1). None of the family members has an overweight. 
Pregnancy was complicated by threatened miscarriage at 16 weeks. He was born at full term, Apgar 
scores were 4 and 8 after 1 and 5 minutes, and soon after birth started to show hypoglycemia, 
hypotonia, bradypnea, and bradycardia. Weight at birth was 3,395 g (50thP), length was 49 cm 
(50thP), and head circumference 35 cm (50thP). He had a cleft palate that was surgically corrected 
at 5 months of age. Growth parameters at 6 months were below 3thP. Several dysmorphisms were 
noticed (Figure 1): a round face, narrow forehead, strabismus, epicanthi, hypertelorism, curly 
eyelashes, sparse eyebrow, broad nasal bridge, small mouth, small chin, and low-set ears. No dental 
anomalies were present. His hands were small and broad with short and proximally implanted 
thumbs and bilateral 5th finger clinodactyly. His genitalia were underdeveloped. He was hypotonic 
and had a diffuse joint laxity and bilateral clubfeet. Skeletal radiographs showed normal bone age, 
a pectus excavatum, lumbar lordosis, hip dysplasia, valgus knee with a left discoid meniscus, and 
bilateral sandal gap. His initial development was normal, language development was regular, and 
he was able to stand up and walk independently at 13 months, although with some clumsiness and 
frequent falls. At 18 months, he started to gain weight and develop an over-eating behavior. At 
evaluation at 17 years, his weight was 120 kg (>97thP), height 160 cm (<5thP), and head circum- 
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ference 60 cm (>97thP). Formal evaluation of cognitive functioning showed mild intellectual 
disability (Wechsler Intelligence Scale for Children––III: QIT 70; QIV 74; QIP 72) and learning 
difficulties. MRI showed enlargement of the cisterna magna and ventricular system, sub-ependymal 
areas of nodular heteroto- pia, a wavy-look corpus callosum, and a mild contrast enhancement of 
the pituitary stalk (Figure 1c). EEG showed no signs of electrical seizures”.  
All the individuals enrolled in the study (probands and parents where available) signed an informed 
consent approved by the Ethics Committee of the referent clinical centres drawn up according to 
current legislation.  
Blood samples (or already extracted DNA) from these individuals were pseudonymized and sent to 
the IRGB-CNR Institute in Cagliari (Italy) and processed for DNA extraction using a standard salting-
out protocol. Red blood cells lysis and separation of a white pellet of white blood cells were obtained 
by osmotic lysis. The cell pellet was resuspended in a lysis buffer, SDS 10% and protein kinase K. At 
the end of incubation, NaCl 6M was added and vortexed to precipitate the proteins. The supernatant 
was transferred into a new Eppendorf tube containing isopropanol and DNA was harvested with a 
pipette tip and dipped in a 70% ethanol Eppendorf tube. Finally, the tubes were centrifuged to pellet 
down the DNA. Supernatant was discarded and DNA air-dried. All the samples were resuspended in 
TE 1-0,1 mM. Samples underwent electrophoresis in 1% agarose gel to evaluated DNA degradation, 
and concentration/purity of double-stranded DNA was measured in Qubit 2.0 fluorometer using BR 
dsDNA Assay Kit (Invitrogen by life technology). 
Whole-Exome Sequencing workflow 
Initially we exome sequenced the samples using the TruSeq Exome Library Prep Kit (Illumina) and 
later with the Nextera Expanded Exome Enrichment Kit (Illumina) when this replaced the previous 
one. Both contain 62 Mb of genomic content, including exons, UTRs and miRNA (> 340,000 95mer 
probes to enrich about 200,000 exons spanning 20,794 genes). The Nextera kit allowed the 
preparation of the genomic DNA library and the exome capture by hybridization in just three days 
instead of 1 week, with an input quantity of DNA of 50 ng instead of 1 µg. 
In general, with all the kits in commerce, the exome library preparation consists of: fragmentation, 
repair of the blunt-ended, adenylation, ligation of the adapters, a first step of PCR, hybridization and 
capture with biotinylate exome probes created in target regions, precipitation with the use of 
streptavidin beads, and a second step of PCR; all interspersed by various purification steps. Adapters 
contain unique index sequences ligated to sample fragments so allowing the pool of more samples 
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and the unique identification of the sequence reads during downstream analysis. Furthermore, with 
the Nextera kit, the fragmentation step is enzymatic rather than mechanic, so being more time-
saving. The last step is the validation of the enriched library performed by the Agilent 2100 
BioAnalyzer with DNA 1000 Kit or High Sensitivity DNA Kit, and Qubit 2.0 using BR dsDNA Assay Kit. 
Libraries were loaded on the cBot System (Illumina) to create clonal clusters on the flow cell and 
then sequenced on the HiSeq 2000 Instrument and analyzed with the Illumina extraction pipeline, 
that consists in a base-calling and imaging analysis performed locally by RTA software. The HiSeq 
2000 uses the Sequencing By Synthesis (SBS) method: a massively parallel sequencing of short reads 
using solid-phase sequencing by reversible terminators, able to generate about 600-700 Gb of 
sequence from over 1 billion clusters in the form of 2×100 base reads (paired-end sequencing) from 
2 flow cells in about 11 days with meagre error rates (< 1%). We obtained a medium coverage of 
about 80X for each sample, and we were able to run 24 samples in a single flow cell.  
We carried out the WES sequencing at the NGS Facility in Pula, directly connected with a high-
performance computing centre and a fully automated infrastructure to support the bioinformatics 
analysis of sequencing data. Furthermore, an optimized variant calling pipeline for WES was 
developed in collaboration with the Center for Advanced Studies, Research and Development in 
Sardinia (CRS4). These analyses have been conducted in collaboration with Dr Fotia’s team at the 
CRS4 Biosciences research and development sector. 
Sequence analysis and variant calling pipeline 
Demultiplexing analysis and generation of FastQ files for the variant calling analysis were 
implemented in Orione, a Galaxy-based framework consisting of publicly available research 
software and specially designed pipelines to build complex, reproducible workflows for next-
generation sequencing data analysis (Cuccuru et al., 2014). It is part of an ongoing project at CRS4 
to integrate Galaxy with Hadoop-based tools to provide scalable computing and a specialized 
version of OMERO to model biomedical data and the chain of actions that connect them. Galaxy is 
used to manage all workflow-based operations, while a custom “Automator” daemon is used to 
execute and monitor workflow progress from the HiSeq instrument to the FastQ files and to link 
workflows to each other. One of the main advantages of this approach is that Galaxy tracks all 
operations with its histories.  
In details, the paired-end sequence reads were aligned to the human genome (hg19) with the BWA-
MEM aligner (BWA v.0.7.5) (Li, 2013). SAMtools were used for converting (SAM/BAM), sorting and 
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indexing alignments. Quality metrics and coverage statistics were calculated with FASTQC and 
Picard tools. First mappings were processed using the GATK framework (GATK v.2.8.1) (McKenna et 
al., 2010) according to their Best Practices recommendations. Briefly, reads were locally realigned 
around known insertion and deletion (INDELs) sites. Those zones are hard to mapping correctly so 
is necessary this step to correct errors made from the first alignment. Then, PCR and optical 
duplicates were marked with Picard tools (v.1.119) and excluded from downstream analysis. Finally, 
raw base quality scores were recalibrated to adjust for quality variation due to machine cycle and 
sequence context, and Single Nucleotide Polymorphisms (SNPs) and insertions/deletions (INDELs) 
were identified using GATK Unified Genotyper. Highly accurate variant calls are identified with GATK 
hard filters. Variants were classified as known or novel variants based on dbSNP146. Different tools 
[GATK Variant Annotator, SnpSift and SnpEff (Cingolani et al., 2012), KGGSeq (Li et al., 2012), SilVA 
(Buske et al., 2013)] were used to annotate variants with position in UCSC, RefGene, Ensembl and 
GENCODE transcripts, OMIM, ClinVar and DDD annotations, potential false positive signals as 
described in Fuentes Fajardo et al., 2012, for maternally or paternally imprinted genes (Joshi et al., 
2016), presence of pseudogenes, allele frequency in dbSNP141, 1000 Genome Project, ESP6500, 
ExAC, Evade v.5 (an internal exome database of ~500 samples) and in a Sardinian population 
database derived from whole genome sequencing (WGS) of 3,500 samples (Sidore et al., 2015); 
sequence conservation, predicted pathogenicity according to different models [non-synonymous 
variants: CADD, SIFT, Polyphen2, LRT, MutationTaster, MutationAssessor and FATHMM retrieved 
from dbNSFP v. 2.9 (Liu et al., 2013); synonymous variants: SilVA], and evidences from literature 
automatically retrieved from PubMed by co-citation of keywords of interest and the genes in which 
the variants are located.  
Sequence data were analyzed with CoNIFER software (Copy Number Inference From Exome Reads; 
Krumm et al., 2012) for the discovery of CNVs in all sequenced patients. CNV calls were annotated 
with CLINGEN (https://www.clinicalgenome.org/) and DGV databases 
(http://dgv.tcag.ca/dgv/app/home).  
These analyses have been conducted in collaboration with Dr Fotia’s team at CRS4. 
Biological interpretation and identification of causal alleles 
On average, exome sequencing identifies ∼24,000 single nucleotide variants (SNVs) in African 
American samples and ∼20,000 in European American samples of whom more than 95% are known 
polymorphisms in human populations (Bamshad et al., 2011). Prioritizing variants in WES studies of 
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Mendelian disorders to finally identify the causal allele can be done at different levels, and it is very 
challenging. 
1. Variant-gene level:  
1.1 Frequency: in rare severe Mendelian disorders, causal variants generally show complete 
penetrance and are rare, and therefore not present in public databases. Ideally, individuals in the 
reference population should have the same origin as the sample under investigation. However, 
because local population frequencies are not always available, public databases are used. Common 
variants deposited in public databases (1000 Genomes Project, ESP6500, ExAC, and dbSNP) are 
filtered out according to an adjustable allele frequency threshold. As most of the disorders under 
study are relatively uncommon and ideally caused by rare pathogenic variants, a filtering exclusion 
based on a minor allele frequency (MAF)>1% is well powered (Bamshad et al., 2011). However, 
caution is necessary given that some of the databases also include patients. Furthermore, an in-
house database of about 500 exomes (Evade v.5) available at CRS4 provides a useful filter to remove 
additional variants, with a 75% increase of the filtering power, for frequency or platform/laboratory 
artefacts.  
1.2 - Gene features: as severe Mendelian disorders are more likely to be caused by non-synonymous 
mutations (missense, nonsense, splice-site defects, frameshift and non-frameshift indels), focusing 
only on this functional class of variants narrows down the number of candidates. Because not all 
non-synonymous variants contribute equally to affect function of coded proteins, a predicted effect 
on protein function and on whether it is potentially disorder-casual is challenging especially for 
missense variants. 
2. Genetic level:  
2.1 Pedigree information: affected family members usually share the genomic segment 
harbouring the causal mutation(s).   
2.2 Mode of inheritance of disorder can also be used to exclude impossible disorder-causal 
variants effectively. We can assume that there are bi-allelic variants for a recessive model 
(homozygous or compound heterozygous with the parents obligate carriers for the variant); 
heterozygous variant for a dominant model (only one parent obligate carrier for the variant or none 
in case of a de novo event); or hemizygous variant for an X-linked model.  
3. Knowledge level: disorder-network analysis added a complementary layer of information to 
the sequencing data. It predicted role in a biological pathway and interaction with genes or proteins 
that were known to cause a similar phenotype and could be used at different steps of analysis. A 
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primary detailed network analysis of the gene(s) harbouring variants genetically and biologically 
validated facilitated the clarification of their putative role in the pathogenesis of the syndrome. It 
could be expected that disruption of the same molecular network could have a similar phenotypic 
effect in general. 
Genetic validation of sequence variants 
Each sequence variant identified during the screening phase as a potential candidate in the 
pathogenesis of the disorders understudy, has been genetically validated by traditional Sanger 
sequencing and disorder-segregation analyses in the family. All family members were sequenced by 
using the sequencer ABI Applied Biosystem 3730 DNA Analyzer, and all the primers were designed 
manually or with the program Primer3. PCR was performed in 25µl of the total volume and 10 to 50 
ng of DNA for problematic samples (mainly degraded samples), 1X buffer, MgCl2 2 mM, 0,12 µM of 
primers, 0,4 U of Taq Polymerase and 0,2 mM of each dNTPs were used. Five µl of Betaine 5M were 
added to the mix to amplify problematic GC abundant sequences. PCR purification was done using 
Exosap according to manufacturer’s protocol. Big Dye v1.1 and relative Buffer 5X were used for 
sequencing the PCR fragment. Then the sequence reaction was precipitated with 95% ethanol, 
sodium acetate 3M pH 5.4.  
 
Results  
Crisponi syndrome/Cold-induced sweating syndrome type 1 (CS/CISS1)-
like phenotypes 
Text extract from Angius et al., 2019: “Here, we identified two de novo missense variants in NALCN 
NM_052867.3: c.1800C>A: p.(Asp600Glu) and c.1571G>A: p.(Ser524Asn) in two unrelated CS 
patients (Family A and C). These novel variants predicted as pathogenic by LRT, MutationTaster, 
Polyphen2 and FATHMM, occurred at highly conserved amino acids within NALCN from different 
organisms, even those very distinct from vertebrates. NALCN forms a voltage-independent, 
nonselective, non-inactivating cation channel permeable to Na+, K+, and Ca (2+). It is responsible for 
the neuronal background sodium leak conductance.6 Functional testing of some human variants in 
Caenorhabditis elegans demonstrated that CLIFAHDD can be caused by dominant loss or gain of 
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function mutations in ion channel function. In 2016, Bend et al7 conducted functional studies on C. 
elegans NCA-1 mutants carrying the p.(Asp647Glu) mutation, which is the orthologous position of 
p.(Asp600Glu) in human NALCN. They described this de novo variant as a gain of function, which 
gives very severe effects. In animal model, this mutation displays dramatically reduced locomotion, 
small body size and curly posture, consistent with neuronal dysfunction. In family B and E, we 
identified two MAGEL2 mutations of paternal origin: a de novo NM_019066.4: c.2056_2066del: 
p.(Trp686Alafs*23), already reported, and an insertion c.1996dupC: p.(Gln666Profs*47): 
rs770374710 which represents a mutational hotspot.8 In family D, we identified a de novo mutation 
in the SCN2A gene, NM_001040143.1: c.2567G>A: p.(Arg856Gln): rs797045942, which has been 
previously reported as associated to Ohthara syndrome. This substitution results in the conversion 
of an arginine to glutamine. This arginine is highly conserved within SCN2A from different organisms, 
even those very distinct from vertebrates. It is predicted to be pathogenic by five popular algorithms, 
SIFT, Polyphen2, LRT, Mutation Assessor, and FATHMM. 
In summary, heterozygous mutations in NALCN, MAGEL2 and SCN2A can result in a CS/CISS-
overlapping phenotype, which seems to be most similar in the neonatal period. Although CS/CISS, 
CLIFAHDD, SHFYNG and EIEE11 syndromes show overlapping features such as feeding problems in 
infancy, contractures and temperature instability, they must be considered as distinct entities. These 
observations suggest that similar pathophysiological mechanisms may lead to such clinically 
overlapping phenotypes. 
Based on the considerable phenotypic overlap between CS/CISS and other syndromes described in 
this article, the clinical geneticist should employ the current clinical diagnostic criteria for CS/CISS 
with caution, especially in the neonatal period. Adequate counseling should only be possible after 
the diagnosis has been confirmed by molecular genetic testing. Therefore, sequencing analysis of 
these genes has to be considered for those cases with a suspected CS/CISS during neonatal period 
who were tested as mutation negative in the known genes, because an expedited and corrected 
diagnosis can improve patient management and can provide a specific clinical follow-up”.  
Epileptic Encephalopathies (EE) 
Text extract from Angius et al., 2018: “Infantile hypotonia with psychomotor retardation and 
characteristic facies-1 (IHPRF1, MIM#615419) is a severe autosomal recessive neurologic disorder 
with onset at birth or in early infancy. It has recently been found to be caused by mutations in the 
NALCN gene that encodes a voltage-independent, cation channel permeable to Na+, K+ and Ca2+.1 
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NALCN forms a channel complex with 2 other proteins, UNC80 and UNC79, involved in the folding, 
stabilization, cellular localization and activation of NALCN. This channel complex is mainly expressed 
in the central nervous system (CNS) and it plays a crucial role in regulating the resting membrane 
potentials and neuronal excitability.2 Recessive mutations in the UNC80 gene are associated to the 
IHPRF2 syndrome (MIM#616801) with a clinical phenotype very similar to IHPRF1.3 UNC79 so far has 
no corresponding human phenotype. 
Only 11 cases from 4 families have been reported in literature as affected by IHPRF1 with 
homozygous mutations in NALCN.1,4,5. We report on 2 additional cases, siblings of a Sardinian family 
presenting with dysmorphic facies, hypotonia, psychomotor retardation, epilepsy, absent speech, 
sleep disturbance, hyperkinetic movement disorder, cachexia and chronic 
constipation”…”Cytogenetic analysis showed a normal karyotype for both patients. Array-based 
comparative genomic hybridization (CGH) analysis, made using commercially available 
oligonucleotide microarrays containing about 60-mer probes (Human Genome CGH Microarray 
244A Kit; Agilent Technologies Santa Clara, USA), and subsequent next generation sequencing (NGS) 
analysis using an Early Infantile Epileptic Encephalopathy panel (ALDH7A1, ARHGEF9, ARX, ATP1A2, 
CACNA1A, CDKL5, CNTNAP2, EFHC1, FOXG1, GABRG2, GRIN2A, GRIN2B, KCNJ10, KCNJ16, KCNK18, 
KCNQ2, MAGI2, MECP2, MEF2C, NRXN1, PCDH19, PLCB1, PNKP, PNPO, POLG, SCN1A, SCN1B, 
SCN2A, SCN9A, SLC25A22, SLC2A1, SLC9A6, SPTAN1, STXBP1, UBE3A) performed according to the 
Roche FLX Titanium protocols, failed to identify any pathogenic variant. 
Whole-exome sequencing (WES) was performed for all family.  Initially, the father was not available 
for testing and he was recruited subsequently after the WES findings. We identified 2 truncating 
mutations in the NALCN gene (NM_052867); chr13:101733940G/A c.3823C>T p.(Arg1275*) 
(rs569371758), maternally derived with a gnomAD reported frequency of 0.000008134 and 
chr13:101759921_101759922insTATGA c.2495_2496insTCATA p.(Phe833Hisfs*40), hypothetically 
paternally derived, never reported so far. Sanger sequencing confirmed both variants in probands 
and parents allowing assessing the clinical phenotype to IHPRF1. This is the fifth family reported 
worldwide, and the first European case with IHPRF1 syndrome. Among all cases, epilepsy is reported 
in 7/11, but EEG characteristics have never been described. 
Although the number of cases with NALCN recessive mutations reported so far is small, we propose 
the inclusion of such gene in the targeted re-sequencing gene panels usually employed in the 
diagnostic setting to identify gene defects associated to epilepsy, also in light of the relevant 
implications in diagnostic workup and therapeutic opportunities.”. 
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Text extract from Alves et al., 2019: “KBG syndrome is a very rare autosomal dominant disorder, 
characterized by macrodontia, distinctive craniofacial findings, skeletal findings, post-natal short 
stature, and developmental delays, sometimes associated with seizures and EEG abnormalities. So 
far, there have been over 100 cases of KBG syndrome reported. 
Here, we describe two sisters of a non-consanguineous family, both presenting generalized epilepsy 
with febrile seizures (GEFS+), and one with a more complex phenotype associated with mild 
intellectual disability, skeletal and dental anomalies. Whole exome sequencing (WES) analysis in all 
the family members revealed a heterozygous SCN9A mutation, p.(Lys655Arg), shared among the 
father and the two probands, and a novel de novo loss of function mutation in the ANKRD11 gene, 
p.(Tyr1715*), in the proband with the more complex phenotype. The reassessment of the phenotypic 
features confirmed that the patient fulfilled the proposed diagnostic criteria for KBG syndrome, 
although complicated by early-onset isolated febrile seizures. EEG abnormalities with or without 
seizures have been reported previously in some KBG cases. The shared variant, occurring in SCN9A, 
has been previously found in several individuals with GEFS+ and Dravet syndrome. 
This report describes a novel de novo variant in ANKRD11 causing a mild phenotype of KGB syndrome 
and further supports the association of monogenic pattern of SCN9A mutations with GEFS+. Our data 
expand the allelic spectrum of ANKRD11 mutations, providing the first Brazilian case of KBG 
syndrome. Furthermore, this study offers an example of how WES has been instrumental allowing 
us to better dissect the clinical phenotype under study, which is a multilocus variation aggregating 
in one proband, rather than a phenotypic expansion associated with a single genomic locus, 
underscoring the role of multiple rare variants at different loci in the etiology of clinical phenotypes 
making problematic the diagnostic path. The successful identification of the causal variant in a gene 
may not be sufficient, making it necessary to identify other variants that fully explain the clinical 
picture. The prevalence of blended phenotypes from multiple monogenic disorders is currently 
unknown and will require a systematic re-analysis of large WES datasets for proper diagnosis in daily 
practice”.  
Syndromic Intellectual Disability (SID) 
Text extract from Angius et al., 2019: “Analysis of WES data yielded the de novo CREBBP variant 
[NM_004380, c.5170G>A; p.(Glu1724Lys)] in the pro- band, confirmed by Sanger sequencing (Figure 
2b and Supporting Information Table S1). No putative causal variants were found in EP300. The 
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Glutamic acid (E) residue at position p.1724 of CBP is located in a conserved residue in the zinc finger 
2 domain (ZNF2, ZZ- type, aa 1,701–1,744) which contains important cysteine residues that mediate 
Zn2+ binding (Figure 2c). Molecular dynamics analyses demonstrated that, within the 3D structures 
of ZZ-domain of CBP, the mutated amino acid (Glu1724Lys) is exposed to the solvent and it is in a 
flexible loop, in particular, it is adjacent to the second conserved, invariable cysteine residue 
(Cys1723) in the Cys-X-X-Cys motif of the second cluster of ZNF2, indispensable for coordination of 
one of the two zinc ions (Figure 2c,d). The change to Lysine (A) is predicted to be “damaging,” 
“deleterious,” or “disease causing” in all functional prediction models and is associated with a very 
high CADD score of deleterious mutation prediction of 54 (Supporting Information Table 2). This 
variant affects the last amino acid of exon 30 where few pathogenic missense mutations have been 
observed (Menke et al., 2018, 1998). The present report adds a further patient to the list of the 22 
reported so far with variants in the last part of exon 30 and the beginning of exon 31, not associated 
with a classical RSTS phenotype. The 25 cases with the new entity do not show the striking facial 
dysmorphisms not the characteristic hand and foot findings of RSTS, although some clinical features 
are shared such as intellectual disability and short stature.”…”The previous reported cluster of 
variants associated to the new phenotype discussed here, is located into the ZNF2 and ZNF3 domains, 
containing cysteine residues that mediated ion zinc binding to stabilize helical folding and mediate 
interactions with transcriptional regulatory proteins (Menke et al., 2018, 1998). Our molecular 
dynamics analyses demonstrated that the mutated amino acid (Glu1724Lys) is exposed to the 
solvent and it is in a flexible loop, in particular, it is adjacent to the second invariably conserved 
cysteine residue (Cys1723) in the Cys-X-X-Cys motif of the second cluster of ZNF2, indispensable for 
coordination of one of the two zinc ions. This suggests that the difference in the electro- static 
potential (polar acidic vs. polar basic) caused by this amino acid replacement could actually play an 
important role in modifying protein–protein interactions and explain the observed phenotype. 
The phenotype of the here presented patient is unusual because of his remarkable obesity which is 
not segregating in this family. Three of the 22 reported patients show obesity as well (Menke et al., 
2018, 1998). More individuals need to be reported to determine whether marked obesity can be part 
of the phenotype. The present brain findings are also unusual, only the enlarged ventricles have been 
reported before (Fergelot et al., 2016). 
In the 2016 article of Menke et al. (Fergelot et al., 2016), it is suggested that the region between the 
last part of exon 30 and the beginning of exon 31 of CREBBP is associated with two different 
phenotypes: the proximal one (as the patient reported here) between bp 5,128 and 5,594 (aa 1,710–
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1864) of CREBBP, in which the present patient's variant is located, shows a less specific phenotype, 
and a more distal one, between 5,595 and 5,614 (aa 1865–1872), in which variants cause a more 
specific and clinically recognizable phenotype. The phenotype of the present patient is in accordance 
with this suggested subdivision. He does share the typical clinical characteristics of this new 
phenotypic entity, such as intellectual disability, short stature, feeding problems, and other 
infrequently findings such as cleft palate, hip dysplasia, sandal gaps, and cryptorchidism. The present 
patient adds as unusual manifestations marked overweight and cerebral heterotopias. However, the 
full variability of the phenotype(s) will only become evident when more patients will have been 
reported in international literature.”  
 
Recently, after the publication of our work, Banka et al., 2019 proposed to call this disorder "Menke-
Hennekam syndrome" (MKHK1; MIM#618332) to establish it as a clinical entity distinct from RTS 
and to provide a satisfactory name for adoption by parents and professionals, thus facilitating 
appropriate clinical management and research.  
 
Discussion 
The results reported here, along with others reported in the literature, are contributing to reveal 
the extensive clinical variability and genetic complexity underlying Mendelian phenotypes and 
inheritance, as well as to provide insight into study design and approach and analytical strategies 
and to identify novel mechanisms (Chong et al., 2015).  
The discoveries of pathogenic variants in NALCN, MAGEL2 and SCN2A, allowed us to reassess the 
clinical phenotype of patients with a suspect of CS/CISS1-like phenotype respectively into CLIFAHDD, 
SHFYNG or EIEE11 syndromes, and although they present with overlapping features especially in 
infancy, such as feeding problems, contractures and temperature instability, they must be 
considered as distinct entities. In particular, our results disclosed both recessive and dominant 
pathogenic variants of human NALCN associated complex neurodevelopmental syndromes. 
Recessive variants of NALCN are linked to the IHPRF1 (MIM#615419) syndrome, while dominant 
variants of NALCN are responsible for the CLIFAHDD (MIM#616266) syndrome. Both IHPRF1 and 
CLIFAHDD patients exhibit complex clinical traits of variable severity that may cause premature 
death in some cases. Notably IHPRF1 and CLIFAHDD patients present with shared symptoms such 
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as facial dysmorphisms, hypotonia, global developmental delay, constipation, and respiratory 
defects (Al Sayed et al., 2013; Chong et al., 2015).  
All these results showing a high neonatal phenotypic overlap among CS/CISS1 with the other known 
syndromes will be very helpful for clinicians. Although clinical expertise allows in some cases to 
make a confident clinical diagnosis, adequate counselling should only be possible after the diagnosis 
has been confirmed by molecular genetic testing. 
The finding of variants in the imprinted MAGEL2 locus shows the importance to consider also 
complex genetic mechanisms, such as genomic imprinting in search of Mendelian disorder-
associated variants. 
Our discovery of a disorder-associated variant in a particular region of the CREBBP gene, implicated 
in the Rubinstein-Taybi syndrome-1 (RSTS1; MIM#180849) but associated to a different clinical 
phenotype, contributed to establish genotype-phenotype correlations in this disorder, and to define 
it as a distinct clinical entity distinct from RSTS1, called Menke-Hennekam syndrome, (MKHK1; 
MIM#618332) to provide a suitable name for adoption by parents and professionals, thus facilitating 
appropriate clinical management and research. So far, only 26 cases have been reported in the 
literature (Menke et al., 2016, 2018; Angius et al., 2019; Banka et al., 2019). 
Furthermore, the discoveries of a novel de novo variant in ANKRD11 causing a mild phenotype of 
KGB syndrome associated to a SCN9A variant causing GEFS+, offers an example of how WES has 
been instrumental allowing us to better dissect the clinical phenotype under study, which is a 
multilocus variation aggregating in one proband, rather than a phenotypic expansion associated 
with a single genomic locus, underscoring the role of multiple rare variants at different loci in the 
aetiology of clinical phenotypes making problematic the diagnostic path.  
From simple beginnings to complex endings 
The pervasive use of WES and approaches using NGS in general, to identify the genetic basis of 
Mendelian conditions, has 1) accelerated the rate of novel Mendelian disorders delineation (known 
gene associated with a novel or different phenotype, or novel gene associated with a novel or known 
phenotype; 2) allowed identification of >1,000 new Mendelian disorders; 3) replaced ‘‘phenotype-
driven’’ with ‘‘genotype-driven’’ syndrome delineation; 4) expanded our understanding about the 
complex relationships between Mendelian phenotypes and their associated genes and genotypes 
(Bamshad et al., 2019). 
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Classically, Mendelian conditions have been categorized as having a dominant or recessive, and 
autosomal or sex-linked pattern of inheritance. However, in the last years, their study has revealed 
the extent to which many rare disorders depart from classical genetic expectations, showing 
complex modes of inheritance (Posey, 2019) instead. It has become clear that conditions whose 
inheritance strictly conforms to Mendelian principles are relatively rare. The growing genome 
complexity is changing the fundamentals based on the paradigm of Mendelian genetics “one gene 
= one disorder” moving far beyond this concept (Katsanis, 2016). 
This extent can be characterized by the occurrence of both dominant and recessive inheritance 
associated with a single locus (i.e. NALCN), the observation of more than one Mendelian condition 
associated with a single locus (i.e. CREBBP), and that a number of Mendelian disorders are not the 
product of a single gene mutation, but of digenic inheritance or of the co-occurrence of two or more 
genetic disorders ((i.e. ANKRD11 and SCN9A; Deltas, 2017; Fernández-Marmiesse et al., 2018). 
It is becoming clear that clinical expertise allows to make a confident clinical diagnosis in a limited 
number of cases and that in most of them, it is necessary to integrate and correlate both molecular 
genetic or genomic data (genotype) with the clinical features (phenotype) of the patient (Wright et 
al., 2018). Clinicians need to consider that rarely a single variant acts in isolation, therefore the 
clinical features presented by an individual may be the result of a mutational burden and compound 
inheritance of rare and common variants that can help to explain the clinical heterogeneity in 
penetrance and expressivity seen between individuals with the same genetic diagnosis, as well as 
the phenotype expansion, that is the expansion of the spectrum of clinical characteristics of an 
explained known Mendelian phenotype (Chong et al., 2015; Wright et al., 2018). Therefore, such 
variation in penetrance and expressivity may suggest that a given trait could be monogenic in one 
individual, and complex in another (Fournier and Schacherer, 2017).  
Inherent to the goal of identifying and characterizing the molecular architecture of Mendelian 
conditions, is the ability to detect with sufficient sensitivity and specificity the relevant types of 
variants (Posey, 2019). 
“Phenotype-driven” to “genotype-driven” 
The definition of a phenotype is an artificial construct useful for clinicians to characterize a particular 
group of patients with particular clinical and physiological measures, and is based on the 
combination of an organism’s observable characteristics or traits, such as its morphology, 
development, biochemical or physiological properties, phenology, behavior, and products of 
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behavior (Chung and Adcock, 2013). Phenotypes depend on both gene inheritance and gene 
expression. So far, delineation of new Mendelian disorders has been mostly done with a phenotype-
driven approach, that is proceeding by collecting multiple individuals with overlapping clinical 
findings and then identifying the underlying gene. Introduction of NGS-based approaches has 
impacted the rate of syndrome delineation, switching from the traditional phenotype-driven to 
genotype-driven method, that is persons with overlapping clinical findings identified only after 
discovery that they share pathogenic variants in the same candidate gene. In the long run, most 
Mendelian conditions will be ascertained via genotype-driven delineation (Bamshad et al., 2019). 
Although our understanding of the variety of Mendelian phenotypes is increasing, significant 
lacunas remain, in particular, as discussed by Chong et al., 2015, in certifying the number of 
Mendelian phenotypes that exist, in defining new Mendelian phenotypes, in discriminating new 
from known Mendelian phenotypes, in delineating what constitutes expansion of a known 
phenotype, in developing measures to define similarities and diversity of phenotypes caused by 
variants in the same gene (Chong et al., 2015). This is in particular due to the variability of “normal” 
human morphology and physiology and to the difficulty in setting limits to define normal versus 
abnormal (Chong et al., 2015).  
Therefore, a key point to achieve the goal of understanding genome function and more importantly, 
its relations to human disorder, is the need for deep-clinical phenotyping in families along with the 
use of WES- and NGS-based strategies (Bamshad et al., 2019).  
WES complementary approaches 
Although current WES- and NGS-based approaches are accelerating the speed of gene discovery for 
Mendelian conditions, the underlying etiologies for approximately half remain unknown (Esplin et 
al., 2014). The strength of the WES to be one of the most cost-efficient sequencing approaches for 
investigating the exome considering that 85% of all mutations that have been identified in 
Mendelian disorders are in coding regions, is also its limit since a substantial fraction of rare disorder 
mechanisms will be intractable to WES. Other limits include technical limitations and more complex 
genetic mechanisms (for example, structural variation, tissue-specific somatic mosaicism, splicing 
and regulatory mutations, genomic imprinting, oligogenic and digenic inheritance, and gene-
environment interactions). Therefore, innovative approaches to address rare disorders caused by 
these mechanisms must be developed to maintain, or even accelerate, the current pace of 
discoveries. Whole-genome sequencing (WGS), in particular, has been considered the logical 
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approach to complement WES for Mendelian gene discovery, especially for the opportunity it 
provides to uncover non-exomic variants and its ability to identify structural variation, but to date, 
WGS has produced few discoveries of novel genes or loci underlying Mendelian disorders. (Bamshad 
et al., 2019; Smedley et al., 2016).  
As with any study, detection rates for both WES and WGS range from 25 to 57% varying with the 
inclusion criteria (Thiffault et al., 2019). Considering that WES would yield the same usable 
information for current clinical analysis, the cost of WGS is presently difficult to justify (Thiffault et 
al., 2019). However, as its cost decreases and the ability to interpret non-coding variants improves, 
the use of WGS over WES will be meaningful (Thiffault et al., 2019). Therefore, until then, periodic 
reanalysis of WES data would be recommended before performing WGS (Costain et al., 2018).  
In addition, WGS presents significant challenges to data interpretation for more than 3 million SNVs 
per sample, and the validation of non-coding variants (as well as coding changes that impact RNA 
expression and splicing) usually requires additional functional studies at the transcriptional level 
(Gonorazky et al., 2019). Recently, the complementation of genetic sequencing with transcriptome 
sequencing (RNA-seq) has successfully improved the diagnostic yield in Mendelian disorders 
through the identification of non-coding variants, deep intronic splice variants and synonymous 
variants with unexpected effects on splicing (Cummings et al., 2017). However, its use is currently 
limited by the restricted access to tissues where the disorder-gene is expresses and by the cost of 
creating transdifferentiated cell lines from affected individuals and controls tissues (Bamshad et al., 
2019). 
Clinical and functional interpretation of variants of uncertain significance 
As the technical limitations of WES are in part overcome by WGS and RNA-seq, the significant 
challenge in Mendelian conditions diagnosis remains the clinical and functional interpretation of 
variants of uncertain significance. The task of assigning pathogenicity to identified variants is critical 
to make a definite diagnosis in the patient (Boycott et al., 2017). 
It is therefore fundamental to improve both computational and statistical models for variant 
identification, annotation, functional prediction, and prioritization—particularly for variants in non-
coding regions, and platforms that store clinical genetic and phenotype data necessary to share 
genomic and phenotypic data openly and at scale worldwide (hundreds of putative gene discoveries 
are unreported buried in medical records, proprietary or restricted-access databases, and scientific 
papers, and most are difficult to access; Bamshad et al., 2017). In particular the availability of 
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population-specific disorder and control databases, the development of in vitro or cell-based 
functional assays applicable to gene regulation or protein function, and simultaneous analysis with 
other broad-based “-omics” approaches such as metabolomics, transcriptomics, or proteomics 
would be critical to clarify the functional effect of the candidate variant (Posey, 2019). 
The possible therapeutic implications are obviously difficult to predict as they presuppose a series 
of elements that are not known a priori, however, the understanding of pathogenetic mechanisms 
is a fundamental prerequisite for adopting specific preventive and therapeutic actions. As sequence 
data becomes available in laboratories, it may be possible to classify patients based on mutated 
genes, identify common phenotypes, or even obtain a sufficient number of affected patients to 
allow for a search for possible modifier genes. 
Despite all these challenges, it is clear that WES has had and will continue to have an increasingly 
profound influence on the genetics and diagnosis of Mendelian disorders, providing more excellent 
timeliness in the diagnosis and administration of appropriate therapies and treatments with a high 
impact in scientific, social, technological and economic terms. 
 
Conclusions 
The study of human genetic diseases has traditionally followed a simplistic categorization. Disorders 
are classified as simple (or Mendelian) vs complex based on family pedigree and recurrence risks in 
individuals with different degrees of genetic relatedness. Likewise, variant forms of the DNA 
sequence of the genes are classified as necessary and sufficient to cause a disease or just 
predisposing based on their alleged phenotypic effect. The recent advent of next generation 
sequencing approaches with the dramatic advance in knowledge of the consequences of genetic 
variation on a large number of increasingly better classified phenotypes is, however, beginning to 
challenge classic definitions of genetic causality.   
In my doctoral work, I provide some further examples showing that beyond the apparent simplicity 
of Mendelian inheritance, there are different and often cryptic levels of difficulty in defining a 
Mendelian phenotype. This emphasizes, the continuous level of the genetic complexity underlying 
phenotypes and the hidden complexity of how genetic variants exert a functional impact 
(Schacherer, 2016).  
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The rare genetic conditions for which the genetic mechanism has yet to be identified are likely 
enriched with those that will not be solved easily by existing WES based approaches (Boycott et al., 
2017). Identifying the molecular basis of conditions intractable to existing approaches requires 
broader and innovative application of existing discovery strategies (e.g., WGS, RNA sequencing), 
improvement of computational and statistical models for variant identification, annotation, 
functional prediction, and prioritization-particularly for variants in non-coding regions; and 
development of strategies for discovering causal genetic mechanisms.  
As more and more genes are discovered to be associated with Mendelian disorders and appropriate 
diagnostic tests are established, a significant challenge in their diagnosis will remain the 
interpretation of a growing number of variants of uncertain significance. This challenge can be 
addressed by the integration of clinical genetic and phenotype data stored in different platforms 
(e.g., ClinVar, Leiden Open Variation Database [LOVD], and DECIPHER), by the availability of 
population- specific disorder and control databases, by the use of broad-based “-omics” approaches 
such as metabolomics, transcriptomics, or proteomics to clarify functional effect (Boycott et al., 
2017). Clearly, the task of assigning pathogenicity to individual variants remains the key to 
diagnostic precision, critical for patient care and must be curated by pertinent experts. 
Moreover, data accumulated from NGS studies supports the awareness that Mendelian and 
complex disorders can now be considered part of one continuum, whereby common and rare 
variants in the context of environmental influences result in perturbation of the biological balance 
of a restricted set of networks activating final common pathways that ultimately cause disorder 
(Lupski et al., 2011) 
 
Take-home messages from Mendelian disorders research 
• "True Mendelian” disorders are very rare: their study has revealed that many rare 
disorders depart from classical genetic expectations, showing instead complex modes of 
inheritance. 
• The growing genome complexity is changing the fundamentals based on the paradigm of 
Mendelian genetics "one gene = one disorder" moving far beyond this concept. 
• In the end most Mendelian disorders will be ascertained via “genotype-driven” 
delineation and not via “phenotype-driven”. 
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• Genetic variation at genes linked to Mendelian disorders plays an important role in driving 
susceptibility to complex disorder. The more we do rare-disorder research, the more we 
then identify cellular pathways and processes that can apply to more-common disorder.  
• The big challenge in Mendelian disorders diagnosis remains the clinical and functional 
interpretation of the huge amount of genetic data generated from these studies.  
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